mipomersen

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
1022 L ow-density lipoproteins (LDLs) are a proven causal risk factor for the development of atherosclerotic cardiovascu-lar… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2013
Review
2013
Mipomersen is a second generation antisense oligonucleotide that targets apolipoprotein B. It has been studied thoroughly in… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
OBJECTIVES This study sought to examine the efficacy and safety of mipomersen for reducing atherogenic lipids and lipoproteins in… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder leading to premature coronary artery… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVES Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
AIMS A randomized, double-blind, placebo-controlled study was conducted to investigate the safety and efficacy of mipomersen, an… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2011
Review
2011
INTRODUCTION mipomersen is a second-generation antisense oligonucleotide (ASO) targeted to human apolipoprotein (apo) B-100, a… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Homozygous familial hypercholesterolaemia is a rare genetic disorder in which both LDL-receptor alleles are defective… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A randomized, double-blind, placebo-controlled, dose-escalation study was conducted to examine the efficacy and safety of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2010
2010
295 eration antisense molecules that is delivered systemically (Nat. Biotechnol. 25, 497–499, 2007). The Carlsbad, California… (More)
  • table 1
Is this relevant?